Shixue Dai

Dr. Shixue Dai

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
CYChen Yang
Chen Yang
XHXiaowen Huang
Xiaowen Huang
YLYan Li
Yan Li
JCJunfei Chen
Junfei Chen
YLYuanyuan Lv
Yuanyuan Lv
SDShixue Dai
Shixue Dai
TP53 mutation is one of the most common genetic changes in hepatocellular carcinoma (HCC). It is of great clinical significance to tailor specialized prognostication approach and to explore more therapeutic options for TP53-mutant HCCs. In this study, a total of 1135 HCC patients were retrospectively analyzed. We developed a random forest-based prediction model to estimate TP53 mutational status, tackling the problem of limited sample size in TP53-mutant HCCs. A multi-step process was performed to develop robust poor prognosis-associated signature (PPS). Compared with previous established population-based signatures, PPS manifested superior ability to predict survival in TP53-mutant patients. After in silico screening of 2249 drug targets and 1770 compounds, we found that three targets (CANT1, CBFB and PKM) and two agents (irinotecan and YM-155) might have potential therapeutic implications in high-PPS patients. The results of drug targets prediction and compounds prediction complemented each other, presenting a comprehensive view of potential treatment strategy. Overall, our study has not only provided new insights into personalized prognostication approaches, but also thrown light on integrating tailored risk stratification with precision therapy.

1 May 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
YCYu-Chen Cao
Yu-Chen Cao
QDQi-Xin Deng
Qi-Xin Deng
SDShixue Dai
Shixue Dai

1 February 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
Yongle ZhanYongle Zhan
Yongle Zhan
YZYong-An Zhan
Yong-An Zhan
SDShixue Dai
Shixue Dai

4 November 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SHShao‐Zhuo Huang
Shao‐Zhuo Huang
ZLZhi‐Cheng Liu
Zhi‐Cheng Liu
WLWei‐Xin Liao
Wei‐Xin Liao
JWJun‐Xiao Wei
Jun‐Xiao Wei
XHXiao‐Wen Huang
Xiao‐Wen Huang
SDShixue Dai
Shixue Dai

31 August 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
ZLZili Lin
Zili Lin
HWHuiyi Wu
Huiyi Wu
YFYiming Fu
Yiming Fu
SDShixue Dai
Shixue Dai
This article is the first review assessing herbaceous plants as a complementary and alternative therapy in inflammatory bowel disease to provide clinicians with more new options.

17 January 2023 in Frontiers in Nutrition
Verified
Journal Article
Open access
YHYue Hou
Yue Hou
SWSai-Feng Wang
Sai-Feng Wang
KZKe Zhou
Ke Zhou
SDShixue Dai
Shixue Dai
Inflammatory bowel disease (IBD), a non-specific chronic idiopathic inflammatory condition of the digestive system, requires lifelong treatment in which drugs are the mainstay, along with surgery when necessary. In adjuvant therapies, the diet is considered to be an essential, controllable, and economical component. However, the majority of recent nutrition research has focused on the general effects of nutrients on IBD, with little attention given to the advantages and negative aspects of individual foods and dietary combinations. To cover these shortcomings, we surveyed the benefits and drawbacks of typical foods and their chemical compositions on intestinal pathophysiology by comparing nutrients existing in the foods in Eastern and Western countries. Moreover, for Eastern and Western patients with IBD, we innovatively propose a 3-step dietary recommendation based on modified customary eating habits, including lowering the triggering foods, modifying dietary advice to control disease progression, and improving surgery prognosis.